Company Description
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Financials, Fundamental Metrics & Ratios
| Revenue (Most Recent Fiscal Year) |
$33.71B |
| Net Income (Most Recent Fiscal Year) |
$12.15B |
| PE Ratio (Current Year Earnings Estimate) |
21.92 |
| PE Ratio (Trailing 12 Months) |
28.32 |
| PEG Ratio (Long Term Growth Estimate) |
0.91 |
| Price to Sales Ratio (Trailing 12 Months) |
9.98 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) |
22.11 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) |
29.07 |
| Pre-Tax Margin (Trailing 12 Months) |
44.13% |
| Net Margin (Trailing 12 Months) |
35.03% |
| Return on Equity (Trailing 12 Months) |
86.32% |
| Return on Assets (Trailing 12 Months) |
27.42% |
| Current Ratio (Most Recent Fiscal Quarter) |
0.94 |
| Quick Ratio (Most Recent Fiscal Quarter) |
0.75 |
| Debt to Common Equity (Most Recent Fiscal Quarter) |
0.43 |
| Inventory Turnover (Trailing 12 Months) |
1.19 |
| Book Value per Share (Most Recent Fiscal Quarter) |
$3.45 |
| Earnings per Share (Most Recent Fiscal Quarter) |
$0.90 |
| Earnings per Share (Most Recent Fiscal Year) |
$2.70 |
| Diluted Earnings per Share (Trailing 12 Months) |
$3.09 |